Ptc Therapeutics, Inc.

Ptc Therpeutics, Inc.

Pct Therapeutics, Inc.

Zhengxian Gu

Jeffrey Allen Campbell

Peter Seongwoo Hwang

Frederick C Lahser

Jason D Graci

Gary Mitchell Karp

Young-Choon Moon

Neil Gregory Almstead

Guangming Chen

James Jan Takasugi

Soongyu Choi

Hongyan Qi

Richard Gerald Wilde

Liangxian Cao

Marla L Weetall

Langdon Miller

Anthony A Turpoff

William Jospeh Lennox

Hongyu Ren

Thomas W Davis

Christopher Robert Trotta

Donald Thomas Corson

Alexander Arefolov

Harry H Miao

Tamil Arasu

Takashi Komatsu

Concetta Freund

Christine Espiritu

Thomas Davis

Maria L Weetall

Jeff Campbell

William Lennox

Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of inhibiting or reducing viral replication or the production of viral RNA or DNA or viral protein using such Compounds, and methods for treating viral infections, such as an RNA virus belonging to the family Coronaviridae, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

Method of inhibiting or reducing a viral infection

Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments. 

Methods for treating cancer and non-neoplastic conditions

The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.

Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent

HCV inhibitor and therapeutic agent combinations

In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

Methods for treating hepatitis C

Growing community of inventors

Princeton, NJ, United States of America

Zhengxian Gu